Clinical data show that over 95% of SMA patients harbor homozygous deletions of SMN1 or gene conversion at exons 7 or 8 from SMN1 to SMN2, whereas the remaining 5% harbor missense, nonsense, and splice site mutations [13]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.